TW200611910A - Interferon-alpha polypeptides and conjugates - Google Patents

Interferon-alpha polypeptides and conjugates

Info

Publication number
TW200611910A
TW200611910A TW094116107A TW94116107A TW200611910A TW 200611910 A TW200611910 A TW 200611910A TW 094116107 A TW094116107 A TW 094116107A TW 94116107 A TW94116107 A TW 94116107A TW 200611910 A TW200611910 A TW 200611910A
Authority
TW
Taiwan
Prior art keywords
conjugates
polypeptides
nucleic acids
interferon
alpha polypeptides
Prior art date
Application number
TW094116107A
Other languages
English (en)
Chinese (zh)
Inventor
Phillip A Patten
Sridhar Viswanathan
Torben Lauesgaard Nissen
Anne Vogt
Harald Kropshofer
Ralf Schumacher
Stephan Fischer
Stefan Seeber
Original Assignee
Maxygen Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc, Hoffmann La Roche filed Critical Maxygen Inc
Publication of TW200611910A publication Critical patent/TW200611910A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW094116107A 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates TW200611910A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19

Publications (1)

Publication Number Publication Date
TW200611910A true TW200611910A (en) 2006-04-16

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094116107A TW200611910A (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Country Status (14)

Country Link
US (9) US7318918B2 (enExample)
EP (1) EP1753779A2 (enExample)
JP (1) JP2008507298A (enExample)
CN (1) CN101115769A (enExample)
AR (1) AR049177A1 (enExample)
AU (1) AU2005245918A1 (enExample)
BR (1) BRPI0511196A (enExample)
CA (1) CA2566247A1 (enExample)
IL (1) IL178470A0 (enExample)
MX (1) MXPA06013412A (enExample)
NO (1) NO20065084L (enExample)
RU (1) RU2006145020A (enExample)
TW (1) TW200611910A (enExample)
WO (1) WO2005113592A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI565714B (zh) * 2011-06-02 2017-01-11 韓美科學股份有限公司 非肽基聚合物-胰島素集合體及其製造方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537762A (ja) * 1999-01-05 2002-11-12 トラスティーズ オブ ボストン ユニバーシティ 改良型核酸クローニング
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
JP2008500750A (ja) * 2004-05-12 2008-01-10 フュージョンワン インコーポレイテッド 高度な連絡先識別システム
ATE540110T1 (de) * 2004-11-11 2012-01-15 Modular Genetics Inc Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt
TWI380993B (zh) * 2005-03-09 2013-01-01 輝陽科技美國公司 重組型超化合物干擾素之用途
CA2607651A1 (en) * 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080014616A1 (en) * 2006-07-11 2008-01-17 Kevin Jarrell Methods of introducing targeted diversity into nucleic acid molecules
US20100009908A1 (en) * 2006-07-25 2010-01-14 Nozomu Nishi Galectin 9-Polymer Conjugates
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
CN101883784B (zh) * 2007-10-01 2014-10-15 药华医药股份有限公司 N-端修饰的干扰素-α
CN101918430A (zh) * 2008-01-18 2010-12-15 弗·哈夫曼-拉罗切有限公司 非糖基化蛋白质的纯化
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
BRPI0916072A2 (pt) * 2008-11-17 2015-11-10 Genentech Inc "uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
EP2726494B1 (en) 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
AU2021210905A1 (en) * 2020-01-24 2022-09-01 Mural Oncology, Inc. Methods of purification
WO2026090002A1 (en) * 2024-10-21 2026-04-30 Pharmaessentia Corporation Mixture of interferon alpha 2b with modified sequences thereof
CN122146562A (zh) * 2026-05-08 2026-06-05 诸城市浩天药业有限公司 一种生产肌醇的重组菌株及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
ES2128348T3 (es) 1990-10-17 1999-05-16 Amgen Inc Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
PT741577E (pt) 1994-03-07 2003-03-31 Imperial College Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
AU775937B2 (en) 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000052153A2 (en) 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
AU8001300A (en) * 1999-10-07 2001-05-10 Maxygen, Inc. Ifn-alpha homologues
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
JP2003513681A (ja) * 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2a 및 2b, 그리고 이들과 PEG유도체와의 배합체
MXPA05005178A (es) 2002-11-15 2005-07-22 Hoffmann La Roche Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg).
NZ540043A (en) 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI565714B (zh) * 2011-06-02 2017-01-11 韓美科學股份有限公司 非肽基聚合物-胰島素集合體及其製造方法
US9944688B2 (en) 2011-06-02 2018-04-17 Hanmi Science Co., Ltd. Non-peptidyl polymer-insulin multimer and method for producing the same

Also Published As

Publication number Publication date
US7541163B2 (en) 2009-06-02
WO2005113592A3 (en) 2006-04-06
IL178470A0 (en) 2007-02-11
CN101115769A (zh) 2008-01-30
US20070225205A1 (en) 2007-09-27
US20070025966A1 (en) 2007-02-01
WO2005113592A2 (en) 2005-12-01
BRPI0511196A (pt) 2007-12-04
US20080171363A1 (en) 2008-07-17
US7537755B2 (en) 2009-05-26
US20080031853A1 (en) 2008-02-07
US7318918B2 (en) 2008-01-15
US20080076710A1 (en) 2008-03-27
US20070020235A1 (en) 2007-01-25
AU2005245918A1 (en) 2005-12-01
US20070225204A1 (en) 2007-09-27
US20050266465A1 (en) 2005-12-01
AR049177A1 (es) 2006-07-05
MXPA06013412A (es) 2007-01-23
CA2566247A1 (en) 2005-12-01
US20070020734A1 (en) 2007-01-25
US7541436B2 (en) 2009-06-02
EP1753779A2 (en) 2007-02-21
NO20065084L (no) 2006-12-01
JP2008507298A (ja) 2008-03-13
US7531324B2 (en) 2009-05-12
US7531630B2 (en) 2009-05-12
RU2006145020A (ru) 2008-06-27

Similar Documents

Publication Publication Date Title
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
WO2006017538A3 (en) Hk1-binding proteins
WO2005007818A8 (en) Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
MX336807B (es) Composiciones y metodos para producir una composicion.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
WO2004078120A3 (en) Collagen compositions and biomaterials
WO2005121331A8 (en) Truncated galnact2 polypeptides and nucleic acids
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
IL185142A0 (en) Lentiviral packaging constructs
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
AU153659S (en) Container
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
ZA200704260B (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
IL187079A0 (en) An oligoadenylate synthetase 1 protein, therapeutic compositions containing the same and screening methods
PL1677818T3 (pl) Stabilne kompozycje wodne zawierające G-CSF
WO2006047728A3 (en) Bmp gene and fusion protein
MY162185A (en) Alumina particles and methods of making the same
AU2003259750A8 (en) Methods and compositions for targeting secretory lysosomes
IL170080A (en) Nucleic acid and protein known as 158p1d7 and their pharmaceutical preparations
WO2005059101A3 (en) Novel sodium channel
MXPA03002581A (es) Composicion a base de copolicarbonatos.
EP1639109A4 (en) DNA VECTORS